Article
FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
Multiple sclerosis and related disorders - 1 Jun 2024
Cui Lei, Jiao Jinsong, Zhang Yeqiong, Wang Renbin, Peng Dantao, Jiao Yujuan, Zhang Weihe
Abstract excerpt
BACKGROUND: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown promise in managing neuromyelitis optica spectrum disorders (NMOSD) by depleting B cells and reducing relapses. However, there is no consensus on the optimal RTX dosing regimen, and genetic factors, such as FCGR3A-V158F polymorphism, may influence treatment outcomes. This study investigates how FCGR3A-V158F genotypes influence RTX efficacy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
